Skip to content

Efficacy of using diabetic specific formula as a meal replacement to control blood sugar level

Efficacy of using diabetic specific formula as a meal replacement to control blood sugar level

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
TCTR
Registry ID
TCTR20230122001
Enrollment
154
Registered
2023-01-22
Start date
2023-06-12
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients with type 2 diabetes more than 6 months and receiving behavioral modification treatment and or receiving Use of diabetes medication without any change in medication during the 3-month period before the study. 1.type 2 diabetes 2.Meal replacement

Interventions

Used as a meal replacement for 1 meal by receiving advice on eating food according tothe American diabetes association (ADA guideline) from a dietitian. Subject will be given to the participants based
D care group, standard group

Sponsors

Faculty of Madicine, Thammasat University
Lead Sponsor
Industrial Technology Assistant Program
Collaborator

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. type 2 diabetes 2. body mass index more than 18.5 kg/m2 3. aged 18 years and over 4. Subjects with FBS > 126 mg/dL and HbA1C than 6.5 but not exceeding 8%, receiving diagnosed for more than 6 months and receiving behavioral modification treatment and or receiving Use of diabetes medication without any change in medication during the 3-month period before the study. 5.Insulin and insulinsecretagogues are not used. 6. Able to eat normally through the mouth 7. can speak and listen to Thai

Exclusion criteria

Exclusion criteria: 1. Pregnant or currently breastfeeding 2. kidney disease stage 3B or more 3. high blood pressure over 180/100 4. history of soybean or dietary constituents in the research. 5. cancer or terminal illness 6. dementia 7. cirrhosis/hepatitis 8.cardiovascular disease who are not able to control their symptoms and still need to adjust their medication.

Design outcomes

Primary

MeasureTime frame
body weight, glycemic, fasting blood, lipid, liver function liver 12 week Kilograms, or mg/dL

Secondary

MeasureTime frame
Consumer satisfaction with experimental food, efficacy in Changes in nutritional status and nutrient energy intake 12 week kcal or g

Countries

Thailand

Contacts

Public ContactAssistant Professor Sanit Wichansawakun

Faculty of Medicine Thammasat University

wichansawakun@gmail.com66816919606

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026